目的 观察贝那普利联合阿托伐他汀钙片治疗冠心病的疗效。方法 2014年2月到2017年1月选择在定边县人民医院诊治的冠心病患者165例作为研究对象，按照纳入时间的先后顺序进行编号，查随机数字表分为观察组83例与对照组82例，对照组给予贝那普利治疗，观察组给予阿托伐他汀钙片联合贝那普利治疗，都治疗观察3个月。比较两组临床疗效，用超声心动仪检测两组左心室舒张末期内径（LVDd）和射血分数（EF），检测两组治疗前后三酰甘油（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）等血脂指标改善情况。结果 治疗后观察组的总有效率为98.8%，对照组为89.0%，观察组的总有效率明显高于对照组，差异有统计学意义（P<0.05）。治疗后观察组与对照组的LVDd值都明显降低，而EF都明显升高，与同组治疗前对比差异有统计学意义（P<0.05）；治疗后观察组的LVDd更低、EF值更高，与对照组对比差异有统计学意义（P<0.05）。观察组与对照组治疗后的TG、TC与LDL-C值都明显低于治疗前，而HDL-C值明显高于治疗前，差异有统计学意义（P<0.05）；治疗后观察组的TG、TC与LDL-C值低于对照组、HDL-C高于对照组，差异有统计学意义（P<0.05）。结论 阿托伐他汀钙片联合贝那普利治疗冠心病用能发挥更好的降脂效应，能促进心功能的改善，提高治疗效果，有很好的应用价值。

Objective: To observe the curative effects of benazepril combined with atorvastatin in the treatment of coronary heart disease. Methods: From February 2014 to January 2017, 165 patients with coronary heart disease in our hospital were selected as the research object, all the patients were randomly divided into observation group of 83 cases and control group of 82 casesaccorded to the sequence of time in number. The control group was given the benazepril treatment, the observation group was given benazepril combined with atorvastatin treatment for 3 months. Results: After treatment, the total effective rate of the observation group was 98.8%, and that of the control group was 89%. The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the LVDd values observation group and the control group were significantly decreased, while the EF values were increased significantly, compared with before treatment were significantly different (P<0.05); the LVDd, EF values in the observation group after treatment compared with the control group were statistically significantly difference (P<0.05). The TG, TC and LDL-Cobservation group and the control group after treatment were significantly lower than those before treatment, while the HDL-C value weresignificantly higher than before treatment (P<0.05), and the TC, TC, HDL-C and LDL-C values in the the observation group after treatment compared to the control group were statistically significantly difference (P<0.05). Conclusion: The Benazepril combined with atorvastatin in the treatment of coronary heart disease can play a better lipid-lowering effect, it can promote the improvement of heart function and improve the therapeutic effect, so it has good application values.